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       ABSTRACT 
Identifying Genomic Signatures for predicting Breast Cancer outcomes 
Shruti Rathnagiriswaran 
Predicting the risk for recurrence in breast cancer patients is a critical task in clinics. Recent 
developments in DNA microarrays have fostered tremendous advances in molecular diagnosis 
and prognosis of breast cancer.  
The first part of our study was based on a novel approach of considering the level of genomic 
instability as one of the most powerful predictors of clinical outcome. A systematic technique 
was presented to explore whether there is a linkage between the degree of genomic instability, 
gene expression patterns, and clinical outcomes by considering the following hypotheses; first, 
the degree of genomic instability is reflected by an aneuploidy-specific gene signature; second, 
this signature is robust and allows breast cancer prediction of clinical outcomes. The first 
hypothesis was tested by gene expression profiling of 48 breast tumors with varying degrees of 
genomic instability. A supervised machine learning approach of employing a combination of 
feature selection algorithms was used to identify a 12-gene genomic instability signature from a 
set of 7657 genes. The second hypothesis was tested by performing patient stratification on 
published breast cancer datasets using the genomic instability signature. The results concluded 
that patients with genomically stable breast carcinomas had considerably longer disease-free 
survival times compared to those with genomically unstable tumors. The gene signature 
generated significant patient stratification with distinct relapse-free and overall survival         
(log-rank tests; p < 0.05; n = 469). It was independent of clinical-pathological parameters and 
provided additional prognostic information within sub-groups defined by each of them. 
The importance of selecting patients at high risk for recurrence for more aggressive therapy was 
realized in the second part of the study, considering the fact that breast cancer patients with 
advanced stages receive chemotherapy, but only half of them benefit from it. The FDA recently 
approved the first gene test for cancer; MammaPrint, for node-negative primary breast cancer. 
Oncotype DX is a commercially available gene test for tamoxifen-treated, node-negative, and 
estrogen receptor-positive breast cancer. These signatures are specific for early stage breast 
cancers.  A population-based approach to the molecular prognosis of breast cancer is needed for 
more rational therapy for breast cancer patients.  A 28-gene expression signature was identified 
in our previous study using a population-based approach. Using this signature, a patient-
stratification scheme was developed by employing the nearest centroid classification algorithm. 
It generated a significant stratification with distinct relapse-free survival (log-rank tests;              
p < 0.05; n =1337) and overall survival (log-rank tests; p < 0.05; n = 806), based on the 
transcriptional profiles that were produced on a diverse range of microarray platforms. This 
molecular classification scheme could enable physicians to make treatment decisions based on 
specific characteristics of patients and their tumor, rather than population statistics. It could 
further refine subgroups defined by traditional clinical-pathological parameters into prognostic 
risk groups. It was unclear, whether a common gene set could predict a poor outcome in breast 
and ovarian cancer, the most common malignancies in women. The 28-gene signature generated 
significant prognostic categorization in ovarian cancers (log-rank tests; p < 0.0001; n = 124), 
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Breast cancer, which originates from the breast epithelial cells, is the most commonly diagnosed 
cancer in women, with an incidence rate more than twice that of colorectal cancer and cervical 
cancer and about three times that of lung cancer. It is the second leading cause of deaths related 
to cancer in women in the United States (1). The National Cancer Institute estimates 182,460 
new cases and 40,480 deaths related to breast cancer among women in the United States in 
20081. Breast cancer is usually treated by removing the tumor and the involved lymph nodes. 
There are different kinds of therapies that frequently follow surgery namely; radiation therapy 
for women who have large tumors or many involved lymph nodes or in case of breast 
conservation, endocrine therapy for women with tumors that express the estrogen receptor 
(ER+), chemotherapy for women who develop a high risk for a poor outcome due to cases such 
as large tumors, involved lymph nodes, advanced disease or inflammatory breast cancer (1). 
Predicting the recurrence of breast cancer is one of the most quintessential tasks for 
physicians. It helps them to determine the most appropriate care based on the individual patient’s 
risk and treatment preferences, especially to avoid harsh therapies that may not be effective2. 
There are different predictive tests that evaluate the risk of recurrence and help the doctors to 







include decisions made on the basis of the location and size of the tumor, the grade and the type 
of the tumor. Numerous novel strategies have been introduced in the last two decades in the 
diagnosis and treatment of breast cancer. An innovative technology namely, genomic-based 
microarray profiling has fostered tremendous breakthroughs in diagnosis and prognosis of breast 
cancer. Using this technology, molecular signatures are identified and serve as a diagnostic tool 
for treating breast cancer.  
Genomic instability, as reflected in heterogeneous nuclear DNA content, serves as one of 
the most powerful predictors of clinical outcome. It is defined as  the loss of stability due to 
abnormal genetic changes occurring serially in cell-populations at a high rate, as they descend 
from the same ancestral cell3.   The importance of genomic instability in the prognosis of breast 
cancer can be reflected by the fact that it causes metastases in breast cancer.  Studies have shown 
that breast cancer patients with genomically stable tumors have considerably longer disease-free 
survival times compared to those with genomically unstable tumors (2;3). In predicting breast 
cancer outcomes, the observations resulting from nuclear DNA content and genomic instability 
were found to be similar to those resulting from  gene expression signatures (4-7).  
Considering these significances of genomic instability, a linkage was established between 
the degree of genomic instability, gene expression patterns, and clinical outcomes in the first part 
of our study. Gene expression profiling of 48 breast cancer patients with varying degrees of 
genomic instability was used and the differences between the groups of genomic instability were 
explored. This led to the development of a 12-gene genomic instability signature.  A combination 







instability signature from an initial set of 7657 genes. The extent to which the genomic 
instability-associated gene expression patterns could allow the prediction of breast cancer 
outcomes was determined using a nearest centroid classification algorithm on 469 patient 
samples. The association between the genomic instability-defined risk groups and traditional 
prognostic factors of breast cancer was studied.  
Two gene expression-based tests have been identified in the recent past to predict the 
outcomes of breast cancer, namely, Oncotype DX, and Mammaprint. Oncotype DX (8) of 
Genomic Health (Redwood City, CA) is the first multi-gene expression test that is available 
commercially. It has the ability to predict the consequences of chemotherapy and recurrence in 
early-stage breast cancer. It has been recommended for patients with lymph node-negative, 
estrogen receptor-positive breast cancer treated with tamoxifen (1), by both the American 
Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network4. 
MammaPrint (9;10) is an another prognostic test for breast cancer recurrence that consists of a 
set of 70 genes. It was commercialized by Agendia (Amsterdam, The Netherlands) and was 
recently approved by the Food and Drug Administration (FDA).  It is recommended for use in 
node-negative women under age 61 and with a tumor size less than 5 cm. However, these tests 
have been identified on particular subgroups of patients. A population-based prognostic gene 
signature is needed for deciding the kind of breast cancer treatment. 
In the second part of our study, a challenging task was sought to accurately classify breast 
cancer patients into subgroups of good prognosis and poor prognosis, in an attempt to improve 







breast cancer patients receive chemotherapy but only half of them benefit from it (11). It is 
critical to select patients at high risk for recurrence for additional chemotherapy. Moreover, this 
part of the study also sought to investigate whether a common gene set could predict poor 
outcomes in both breast and ovarian cancer, considering the fact that women with breast cancer 
are easily susceptible to ovarian cancer according to epidemiological studies (12).  
   This part of the study sought  to validate the predictive power of a 28-gene expression 
signature that was identified in our previous study (13)  using a population-based approach to the 
molecular prognosis of breast cancer. The training dataset contained 99 patients having different 
histologies, while the validation datasets contained a total of 1734 breast cancer patients with 
heterogeneous disease stages, having gene expressions generated from different microarray 
platforms, and 124 ovarian cancer patients with advanced stage (III or IV). A scheme was 
developed for applying the prognostic gene signature in patient stratification, based on 
transcriptional profiles generated on a diverse range of microarray platforms, using a nearest 
centroid classification (NCC) algorithm. The association between the gene signature and 
traditional clinical-pathological factors was accessed in quantifying breast cancer disease-free 
survival and overall survival. 
The thesis is organized as follows. Chapter 2 discusses the background of our study, 
Chapter 3 elucidates the development and validation of the 12-gene genomic instability 
signature, Chapter 4 describes the validation of the 28-gene expression signature that was 











The three primary concerns in cancer prediction/prognosis are as follows: 1) the prediction of 
cancer susceptibility where, one tries to predict the likelihood of developing a type of cancer 
prior to the occurrence of the disease, 2) the prediction of cancer recurrence where, one tries to 
predict the likelihood of redeveloping cancer after the apparent resolution of the disease, 3) the 
prediction of cancer survivability where, one tries to predict an outcome after the diagnosis of the 
disease (14). In the latter two cases, the success of the disease prognosis is dependent on the 
quality of diagnosis.  
Machine Learning is a part of artificial intelligence that uses statistical, probabilistic and 
optimization tools to study existing examples and then uses the “prior” information to classify 
new data or identify new patterns (14).  Machine learning methods have been used extensively in 
the past as an aid for cancer diagnosis, but recently, researchers have started applying machine 
learning techniques for cancer prediction and prognosis too (14). 
The remainder of the chapter is organized as follows. Section 2.2 describes gene 
expression profiling, Section 2.3 discusses the need for feature selection, Section 2.4 reviews the 
machine learning algorithms that were used in our research, Section 2.5 and Section 2.6 explain 
the statistical methods that were adopted in our research, Section 2.7 reviews the related work 








Gene Expression Profiling or Microarray analysis is an emerging technology for identifying 
genes. It has been successfully used in the prognosis and therapy of breast cancer and other 
diseases in the recent years. This has been accomplished by a variety of microarray platforms. In 
this analysis, the composition of cellular messenger ribonucleic acid (mRNA) is identified. It 
provides the measure of the number of mRNA transcripts derived from a gene (1). This 
technology involves several thousands of genes and thus causes the dimensionality to be very 
high. It becomes a major limitation in many pattern recognition problems when the sample size 
is small. Moreover, the large number of features leads to the degradation in the performance of 
the classifiers, if the number of samples is relatively very small. This causes the problem of 
‘Curse of dimensionality’ which is a term coined by Richard Bellman that describes the problem 
caused by the exponential increase in volume as a result of adding extra dimensions to a space5. 
In the case of cancer classification, the number of genes is as large as thousands of genes but the 
number of samples is relatively small because of the limitations in the availability of samples, 
acquisition, time and cost (15).   
2.3  Need for Feature Selection 
 
Large number of features in a high dimensional dataset causes noise and introduces an error. 
Moreover, not all the features are important for performing an analysis on the dataset. This can 
be explained mathematically by considering a p-dimensional random variable X such that  







S is a k-dimensional subset of X having lower dimensions and is represented by  
 S = (s1, s2, s3…sk) T                                                                     (2.2) 
where k ≤ p and S contains the important features extracted by using some algorithm      
(criterion) (16). Another drawback with high dimensional datasets is that they may require more 
samples or observations to extract the important features.  
The problems associated with the high dimensional datasets can be minimized by having 
a priori information about the features. The process of extracting important and relevant features 
is called Feature Extraction. This is usually done by employing machine learning algorithms. 
Basically, in this process, a subset of input variables is selected by eliminating features with little 
or no predictive information.  
Feature selection can significantly improve the comprehensibility of the resulting 
classifier models and often builds a model that generalizes better to unseen points. Feature 
selection is thus defined as a process in which a data space is transformed into a feature space 
that, in theory, has exactly the same dimension as the original data space. However practically, 
the transformation involves a reduction in the number of the effective features but retains most of 
the intrinsic information of the data. Thus, this technique aims to minimize information loss 










This section talks about the various classification algorithms that we used in our research to 
obtain the gene signatures. 
2.4.1   Naïve Bayes Algorithm 
 
The Naive Bayes algorithm is a machine learning algorithm used for classification. It is based on 
Bayes rule that makes two assumptions; 1) the attributes X1…. Xn are all conditionally 
independent of one another, given the class Y , 2)  the predictive process is not influenced by any 
hidden or latent attributes (17;18).  It is usually employed in supervised induction tasks, in which 
the ultimate goal is to accurately predict the class of test instances when the training instances 
include class information (18). 
From the definition of conditional independence, given random variables X, Y, Z; X is 
conditionally independent of Y given Z, if and only if the probability distribution of X is 
independent of the value of  Z; mathematically, (17)  Y given
      ( , , P(X=xi |Y=yj, Z=zk) = P(X=xi |Z=zk)        (2.3)  
If X denotes a vector of attributes [x1, x2] and Y denotes a class, 
    P (X|Y) = P(x1, x2|Y)                                                            (2.4) 
from general property of probabilities 
      = P (x1|x2, Y) P (x2|Y)                                      (2.5) 
from (2.3) 
                                                = P (x1|Y) P (x2|Y)                                                                            (2.6)                         
Thus it can be summarized that, if X contains n attributes which are conditionally independent of 





                                          P (X|Y) = P(x1, x2, …, xn |Y) = ∏ i|Y)        (2.7) 
         
From Bayes Rule, we have  
     P(Y= yk | x1..xn) =     
       ∏  |    
∑       ∏ |      
               (2.8) 
         
Where Y is a discrete-valued variable denoting the class and x1...xn are the discrete-valued 
attributes. Equation (2.8) represents the fundamental equation for Naïve Bayes Classifier (17). 
The Naïve Bayes Classification rule is used to calculate the most probable class to which an 
unknown sample belongs to (17).  It is given by the equation. 
      Y   arg max yk        
       ∏  |    
∑       ∏ |      
       (2.9)   
                               
Since the denominator is independent of y u  be reduced to
            
k, the equation (2.9) can f rther
       Y  arg max yk   ∏ |             (2.10)  





Random Forests is one such classification algorithms that directly provides measures of variable 
importance related to the relevance of the variable in the classification. Developed by Leo 
Breiman, this classification algorithm employs an ensemble of classification trees. The tree is 
built using bagging and random variable selection that results in the low correlation of the 
individual trees. In order to obtain low-bias trees, they are left unpruned. The fundamental 
principle governing random forests is that for each tree, a  random vector is generated such that it 





using the training set and the random vector together as inputs (19). This algorithm can also be 
used for feature selection. 
The foremost step of random forests is to form diverse tree classifiers from a single 
training set.  Each tree is built upon a random sample taken with replacement from the training 
set. This is called “bootstrap sample”. A random subset of the whole variables set is used for 
splitting the tree nodes. The classification decision of a new case is obtained by majority voting 
over all trees unless the cut-off value is user defined.  In random forests, about one-third of the 
cases in the bootstrap sample are not used in growing the tree. These cases are called             
“out-of-bag” (OOB) cases and are used to evaluate the algorithm performance.  
There are two measures of importance provided while implementing Random Forests in 
software package R; “mean decrease in accuracy” and “mean decrease in gini”. Mean decrease 
in accuracy considers the importance of an mth variable as the difference between the             
“out-of-bag” error rate for the randomly permuted mth variable (the error rate obtained by 
randomly rearranging the values of the mth variable for the out-of-bag set, for each tree, and 
getting new classifications for the forest, by putting this permuted set down the tree.) and the 
original “out-of-bag” error rate.  Mean decrease in gini considers the importance of an mth 
variable as the sum of all decreases in impurity (measured by gini index) in the forest due to this 
variable, normalized by the number of trees (20).  
The qualities that make  Random Forest an ideal classifier are (19). 
• It has good predictive performance even when there is noise in the predictive variables.  





• It can be used both for problems involving two classes as well as multiple number of 
classes. 
• It gives the measures of variable gene importance. 
• It involves little need to fine-tune the parameters to achieve excellent performance. 
2.4.3   Random Committee 
 
It is one of the metalearning algorithms used in machine learning that takes classifiers and 
converts them into more powerful learners. Random Committee builds an ensemble of 
randomizable base classifiers by taking random samples of the same dataset and considering 
different random seed every time a classifier is built. The final prediction is the average of the 
predictions made by individual classifiers (17;21).  
2.4.4  Relief Algorithm 
 
Relief is an instance based attribute ranking scheme introduced by Kira and Rendell (22). Using 
this algorithm, the relevance of a feature can be found by estimating its ability to distinguish 
samples near to each other. The basis on which the algorithm works is that in dimensions of 
relevant features, the closest sample of the same class is expected to be closer than the closest 
sample of other classes (23). 
Let us consider N training samples:  
{x(1),c(1)},{x(2),c(2)},{x(3),c(3)},…..,{x(N),c(N)}      
Where x (k) =[x1(k), x2(k), x3(k),…, xn(k)] is the feature vector of sample k.  x1, x2 ,x3,….xn  are 
the  available features, and c(k) is the class to which the sample k belongs .  





      C1 =   ∑ | i(k) ­ xiM(k)| ­ |xi(k) ­ xiH (k)|]     (2.11) 
 
Where xiM(k) denotes the values of feature of the nearest-miss and xiH (k) denotes the values of 
feature of the nearest-hit samples of sample k. The nearest-hit sample is a term referring to the 
nearest neighboring sample of the same class, while the nearest-miss sample refers to the nearest 
neighboring sample of the different class (23). Relief was defined for problems involving 2 
classes and was later extended to Relief F algorithm that had the capability to handle noise and 
multiple datasets (24). 
2.4.5   Nearest Centroid Method 
 
Nearest centroid method is a fast and simple algorithm used for classification that works on the 
basis of classifying an unknown instance to the class whose centroid is closest to it.  It considers 
the centroid of the cluster as a representative of the class.  The learnt distance function is used to 
determine the closest centroid (25). 
The arithmetic mean of a class C  represents the prototype pattern for the class and is denoted by j
          µCj =  | | ∑ i          (2.12) 
where xi represents the training samples that have the class Cj. 
Using this algorithm, a class label of an unknown instance x is predicted as: 
      C(x) = arg min Cj d (µCj, x)                   (2.13) 
where d(x,y) denotes the distance function (26). 
The distance function measures the strictness of dependence between the two vectors (27). This 
method is usually preferred in biological applications because of its favorable invariance 
properties i.e. the correlation between the variables is not affected by an addition of a constant 






Pearson Correlation provides the degree of linear dependence of vectors x and w by  
                                          R (x, w) =     
∑   .
∑   . ∑ µ
                                (2.14) 
where µ  and µ  are the respective means of the vectors x and w. The equation is standardized 
by the multiplication of the standard deviations of the vectors after subtracting their respective 
means. This causes the Pearson correlation to be invariant (27). 
The nearest centroid classification is an efficient method for classifying the new instances 
without any feature selection. It is one of the simplest and extremely fast classifier. For cases 
involving two classes, the nearest centroid algorithm is linear and implicitly encodes a 




Kaplan-Meier analysis is a recommended statistical technique used in clinical trials for 
estimating the proportion of the population of people who would survive a given length of time 
under the same circumstances, given a set of observed survival times including censored times 
(times for which the period of observation was cut-off before the event of interest occurred) (28). 
It is a non-parametric (actuarial) technique that estimates time-related events6  by 







This analysis allows estimation of survival over time even when patients are censored 
(dropped out or are studied for different lengths of time)7.  It is usually followed by plotting the 
cumulative survival function on a linear scale with the time on the x-axis and the cumulative 
survival on the y-axis. The curve generally slopes down with fewer surviving cases as the time 
increases. The plot is generally a step function, in which the estimated survival probabilities are 
constant between adjacent death times and decrease at each death (28). The steepness of the 
curve indicates the efficacy of the treatment being investigated.  Kaplan-Meier curves can also 
be used to test the statistically significant differences between the survival curves associated with 
two different treatments (29). 
2.5.2  Mathematical Expression 
Let us assume that there are N individuals observed from time 0 to sometime T, the true survival 
time of each individual is Xi and the distribution function is  
     F*(x) = P (Xi ≤ x)                    (2.15) 
Let the survival function be  
     F(x) = 1- F*(x)         (2.16) 
Let the censoring variables Yi be independent of the survival variables Xi and have the 
distribution function  
 H*(y) = P (Yi ≤ y)         (2.17) 







 Let H (y) = 1-H*(y)        (2.18) 
Let the observed survival times be denoted as ti where  
     ti = Xi when Xi ≤Yi and Xi < T.        (2.19) 
The Kaplan-Meier estimate FN(t) is computed by ranking the values ti in ascending order t1 ≤ t2 ≤ 
t3... ≤ tn  where, where tj  is the jth largest unique survival time (30).  
The estimated conditional probability of surviving beyond time tj is  
      Pj = 1-                             (2.20) 
Where dj is the number of individuals who experience the event of interest at time tj, and rj is the 
number of individuals at risk just before tj, inclusive of those censored at tj. Basically, the 
estimated conditional probability represents the ratio of the number of patients surviving beyond 
time tj to the number of patients at risk (28;30).  
Thus the Kaplan-Meier estimate is the product of these conditional probabilities (28).  
      FN(t) = ∏ j      for  ti ≤ t ≤ ti+1           (2.21)  
2.5.3  Log­ rank test 
 
Log-rank test is a hypothesis test and is the most popular test for comparing the survival of 
groups. It is a non-parametric test and is sometimes called as Mantel-Cox test. It considers the 





censoring is non-informative either because there was no event observed till the end of the study 
or  the individual lost to follow-up or the event was not recorded properly 8. 
  This test was first proposed by Nathan Mantel and was named “log-rank test” by Richard 
and Julian Peto9. The advantage of using the log-rank test is that we need not have prior 
knowledge of the shape of the survival curve or  the distribution of survival times (31).  
The null hypothesis considered in this test is that there is no difference between the 
populations in the probability of an event (relapse or death) at any time point. The analysis is 
based on the times of events (31).  It calculates the observed number of deaths and the expected 
deaths in each group for each observed time. It thus compares the estimates of the hazard 
functions of the two groups at each observed time. 
When the risk of an event is consistently greater for one group than the other, the        
log-rank test most likely detects a difference between the groups. However, it is unlikely to 
detect a difference when survival curves cross. When there is no censorship (loss to follow-up) 
the log rank test gets reduced to Mann-Whitney test (two-sample Wilcoxon test) for two groups 
of survival times and Kruskal-Wallis test for more than two groups of survival times10.  
The log-rank test compares each observed event in group i at a distinct time j; Oi j to its 









                                          Z = 
∑
∑
         (2.22) 
where Vj is the variance of the distribution at the distinct time j11. 
2.6  Cox Proportional Hazard Model 
 
Cox proportional hazard model, introduced by Sir Cox in 1972 (32) is a highly-well recognized 
statistical technique that finds application in the field of medical statistics. It introduces a 
modeling approach to analyze the survival data and enables one to explore the relationship 
between the survival of a patient and several explanatory variables (28).  It is extremely useful in 
the cases that involve more than one explanatory variable.  It provides an estimate of the risk of a 
patient towards an event (relapse or death) for individuals, given their prognostic variables. This 
model generates the coefficients for each explanatory variable. The interpretation of the 
coefficients is as follows: a negative value for the regression coefficient implies lower hazard 
risk or better prognosis; a positive value for the regression coefficient implies higher hazard risk 
or poor prognosis.  
 The main factor governing the survival function is the hazard function h(t) which is 
defined as the probability that an individual experiences an event in a small time interval given 
that the individual has survived to a time up to the beginning of the interval (33).  It is expressed 
as  







Or       
      h(t) = 
                       
                    
     (2.24)             
Let us consider that there are n explanatory variables expressed as x1,x2, x3, …. xn. The hazard 
function is then expressed as  
 h(t) = h0(t) x exp(β1.x1 + β2.x2+ β3.x3 …. + βn.xn)                          (2.25) 
where β1 to βn  represent the regression coefficients that are generally estimated by a statistical 
method called maximum likelihood (28). 
Taking the natural logarithms on both sides of the equation, we get 
                                          ln h(t) = ln h0(t) + β1.x1 + β2.x2+ β3.x3 …. + βn. xn                      (2.26) 
The factor h0(t) is known as baseline hazard function which represents the hazard function for 
the patients when all the explanatory variables are zero. The exponential of the regression 
coefficients; exp (βj) provides the relative risk change that is associated with the increase of the 
covariate xj by one unit. The significance of each variable is obtained by dividing the regression 
coefficient by its standard error (measure of uncertainty of an estimate), and comparing this 
value with the standard normal distribution. A value > 1.96 is implies that the variable is 
statistically significant (28).  
This model yields an equation for the hazard as a function of several explanatory 
variables and forces the hazard relation between the two patients to be constant over time. Thus, 






There have been numerous studies in the past, related to the application of machine learning in 
breast cancer prediction and prognosis. This section discusses in brief about such studies. 
Sotiriou et al. (34) adopted a population-based approach to determine the genes 
associated with improved relapse-free survival. They identified a set of 485 probe elements from 
a total of 7650 probe elements by performing Cox proportional hazard regression analysis. This 
set could separate the relapse-free survival in 99 patients with a p<0.05. 16 probe elements were 
significantly associated with relapse-free survival at a stringent significance level of p<0.001. To 
identify a minimal number of the most important prognostic genes, the list of 485 probe elements 
was overlapped with 231 genes present in the prognostic gene set in van’t Veer et al. (9). This 
overlap resulted in 11 unique genes represented by 14 probe elements.  
van’t Veer et al. (9) reported the development data for the 70-gene set which was 
identified from 117 primary breast tumors, analyzed on DNA microarray platform that contained 
25000 genes. This gene set is the basis for the MammaPrint test (1). Van de Vijver et al. (10)  
performed the first major validation of the 70-gene signature that was reported in van’t Veer et 
al. (9)  by classifying a series of 295 patients with primary breast carcinomas to poor prognosis 
or good prognosis using microarray analysis.  
Sorlie et al. (35;36) classified breast carcinomas that were based on variations in gene 
expression patterns derived from cDNA microarrays, and correlated the tumor characteristics to 
clinical outcome. They found that this classification could be used as a prognostic marker for 
relapse-free and overall survival in a subset of patients who received uniform therapy. It was 
reported previously that cancers could be classified into groups such as, basal epithelial-like 





expression. Sorlie et al. (36) found that the previously characterized luminal epithelial/estrogen 
receptor positive group could be divided into at least two subgroups, each with a distinctive 
expression profile. They further refined the previously defined subtypes of breast tumors that 
could be distinguished by their distinct patterns of gene expression, by analyzing 115 malignant 
breast tumors using hierarchical clustering.  
Wang et al. (37) identified a 76-gene signature from a training set of 115 tumors, of 
which there were 80 estrogen receptor (ER)-positive and 35 ER-negative tumors. The patients 
were grouped on the basis of the ER status, and each subgroup was analyzed separately for the 
selection of biomarkers. The 76-gene signature was obtained from a combination of 60 genes 
that were identified from ER-positive subgroup, and 16 genes from ER-negative subgroup. This 
signature served as a powerful tool for identification of patients at high-risk of distant recurrence.  
Bild et al. (38)  identified gene expression signatures that reflected the activation status of 
several oncogenic pathways. They evaluated these gene expression signatures in several large 
collections of human cancers, resulting in identification of patterns of pathway deregulation in 
tumors and association with disease outcomes.  
Miller et al. (39) identified a 32-gene expression signature that distinguishes p53-mutant 
and wild-type tumors of different histologies, by analyzing transcript profiles of 251 p53-
sequenced primary breast tumors.   
Ivshina et al. (40) identified 264 robust grade-associated markers from a study of 
expression profiles of 347 primary invasive breast tumors analyzed on affymetrix microarrays. 
Class prediction algorithms were used, six of which could accurately classify Grade 1 and Grade 






Loi et al. (41) assigned ER-positive breast cancer patients to either high or low genomic 
grade subgroups by using the gene expression grade index (GGI) algorithm which defines 
histological grade based on gene expression profiles. These subgroups were compared with 
previously reported ER-positive molecular classifications. 
2.8  Summary 
 
This chapter reviewed the various machine learning algorithms and the statistical techniques that 
were employed in our research. The related work done in other previous studies were briefly 
discussed. These studies have adopted the common practice of identifying a gene signature by 
using only one machine learning algorithm. Nevertheless, the high dimensionality of DNA 
microarray data requires integrating multiple feature selection algorithms at different stages of 
gene selection to obtain better performance. We thereby developed a scheme to combine   
several feature selection algorithms to identify novel disease biomarkers. The data from various 
publications were used in the identification and validation of the gene signatures. The subsequent 













In this study, we recognized that the level of genomic instability (as reflected by the variability 
of DNA content; aneuploidy) is strongly associated with breast cancer prognosis (4;5). In 
predicting breast cancer outcomes, the observations resulting from nuclear DNA content and 
genomic instability were found to be similar to those resulting from gene expression signatures 
(4-7). Moreover, Kaplan-Meier curves that assessed the recurrence-free survival were identical 
when using either gene expression signatures or genomic instability as independent variables. 
These facts provoked the assumption that the two are connected. We sought to determine the 
nature of the connection by considering the following hypotheses: first, the degree of genomic 
instability is reflected by an aneuploidy-specific gene signature (set of genes with large 
variability in DNA content); second, this signature is robust and allows breast cancer prediction 
of clinical outcomes in independent datasets. The first hypotheses was tested by gene expression 
profiling of 48 breast cancer carcinomas with defined patterns and varying degrees of genomic 
instability; whereas, the second hypothesis was tested through classification of published breast 
cancer datasets using the gene expression signature of genomic instability. 
In this chapter, we discuss in detail about the development and validation of a 12-gene 
genomic instability signature that resulted from an attempt to explore the differences between 
different genomic instability groups. It was identified from a dataset that contained gene 





genomic instability. A supervised machine learning approach was adopted in multiple settings 
for performing feature selection using a data-mining tool, WEKA12.  
 Next, the extent to which the gene expression signature (that defined genomic instability) 
could predict the breast cancer outcomes in previously published datasets was determined. This 
was accomplished by using the nearest centroid classification algorithm to perform patient 
stratification in the validation datasets. The significance of this stratification was tested using 
Kaplan-Meier analyses followed by log-rank test in R13.  
The association between the genomic instability-defined risk groups and traditional 
prognostic factors of breast cancer such as lymph node status, tumor grade, NIH consensus 
criteria (42) and St.Gallen criteria (43) was evaluated. Furthermore, it was investigated whether 
the 12-gene genomic instability signature could provide additional prognostic information, 
within the subgroups defined by traditional clinical-pathological factors. 
The remainder of this chapter is organized as follows: Section 3.2 briefly introduces the 
datasets that were used in this study, Section 3.3 discusses the process of biomarker 
identification,  Section 3.4 elucidates the validation of the genomic instability gene signature for 
disease-free and overall survival prediction on previously published datasets, Section 3.5 
discusses the association of the gene expression-defined groups and clinical parameters, and 













 The data that was used as a training dataset was obtained from Dr. Thomas Ried, NCI. This data 
contained 7657 genes and 48 primary breast cancer specimens collected at the Karolinska 
Institute and Hospital, Stockholm, Sweden during 2000 and 2001.  The data was analyzed using 
global gene expression profiling on cDNA arrays. This analysis was complemented by mapping 
of genomic imbalances using comparative genomic hybridization. 17 of these tumors were 
classified as diploid; genomically stable (dGS), 15 as aneuploid; yet genomically stable with a 
defined stemline (aGS), and 16 as aneuploid and genomic unstable (aGU). This dataset was 
subjected to quality assessment and 4 samples were discarded as they did not pass the quality 
assessment criteria. Finally, there were a total of 44 samples; 14 dGS, 14 aGS, and 16 aGU.  
The validation datasets were obtained from various patient cohorts mentioned in previous related 
publications. The following datasets were used as validation datasets.  
1) Sotiriou et al. (34) (PMID: 12917485) - This cohort contains 99 node-negative and node-
positive breast cancer patients. All of the tumor samples were invasive ductal carcinomas; 46 
individuals were node-negative and 53 were node-positive; 16 patients with tumor grade 1, 38 
patients with tumor grade 2, and 45 patients with tumor grade 3; 65 estrogen receptor           
(ER)-positive and 34 ER-negative patients. Two patients received PMF Chemotherapy; 30 
patients received CMF; and two received Adr, CMF chemotherapy. The dataset is publically 







2) Sorlie et al. (35) (PMID: 11553815) - This cohort contains 75 breast carcinomas (66 ductal, 
five lobular, 1 pleomorph, 1 mucinous, 1 papillary and 1 DCIS). Fifty-one patients were treated 
with doxorubicin monotherapy before surgery followed by adjuvant tamoxifen in the case of 
positive ER and/or progesterone receptor (PgR) status. This cohort contains 56 ER-positive 
patients and 17 ER-negative patients. Nine patients had Grade 1, 33 patients had Grade 2, and 32 
patients had Grade 3.  The cohort contains 23 lymph node-positive and 52 lymph node- negative 
patients. The dataset is publically available at the Gene Expression Omnibus database with the 
accession number GSE3193.  
3) Van de Vijver et al. (10) (PMID: 12490681) - There were 295 consecutive patients with 
primary breast carcinomas, 151 with lymph node-negative disease, and 144 with lymph node- 
positive disease. The dataset is publically available at the Rosetta Inpharmatics website15 
3.3   Biomarker Identification 
 
This section describes the identification of the genomic instability signature. A supervised 
machine learning approach involving a combination of feature selection algorithms was adopted 
in two sample settings, to identify a genomic instability signature from the expression profiles of 
7657 genes on 44 breast cancer samples. In the first setting, a binary classification was done to 
explore the differences between the genomic stable and the genomic unstable group. To 
accomplish this, feature selection was performed on the dataset using Random Forests with the 
help of varSelRF package in R (33). This algorithm builds trees upon a bootstrap sample. The 







growing the trees, namely, out-of-bag (OOB) cases.  This algorithm was carried out in a series of 
following steps: 
1. A large forest with 2000 trees was built based on all of the 7657 genes and the importance 
measure of the genes was obtained. 
2. 20% of the least important genes were filtered out and a forest was built with the remaining 
number of genes to get the OOB error estimate. 
3. The step 2 was repeated until one or two genes were left, and 
4. The gene set which had the smallest OOB error rate was selected. 
In this process, a set of 7 genes was selected that had the smallest OOB error rate. Table 3.1 
enlists the 7-gene signature. 
Table 3.1: List of 7-gene Signature 
GENE NAME MAP CLONE ID 
HNF3A—hepatocyte nuclear factor 3, al 14q12-q13 1711594 
Homo sapiens mRNA; cDNA DKFZp762M127 11 1822809 
STK15—serine/threonine kinase 15 20q13.2-q13.3 2007691 
KIAA0882—KIAA0882 protein 4q31.1 2190664 
MYB—v-myb avian myeloblastosis viral oncog 6q22-q23 2555590 
RERG—RAS-like, estrogen-regulated, gr 12p13.1 644989 
Incyte EST NaN 88935 
 
The classification accuracy of the selected gene set was evaluated using the Random 
Committee algorithm in WEKA (44) with a leave-one-out cross validation. We performed 
several experiments using the algorithms implemented in WEKA, and selected Random 





genomic stability (dGS + aGS) vs. instability (aGU). This algorithm generated a classification 
accuracy of 93.18%. The percentage of correctly classified genomically stable (aGS +dGS) 
patients was 92.86% and that of the genomically unstable (aGU) patients was 93.75%. The 
results of the binary classification are represented graphically in Figure 3.1. 
 
 




In the second setting, the differences among the three groups were explored by 
performing a multi-classification. Feature selection was performed in a similar manner using 





enlists the list of 70-gene signature. This gene signature was further subjected to feature selection 
using Relief algorithm in WEKA (24) which ranked the 70 genes in the order of importance. The 
top 10 genes were selected from the 70-gene set. Table 3.3 enlists the list of 10-gene signature. 
Table 3.2: List of 70 gene signature 
Clone ID Gene Name 
1269591 Homo sapiens mRNA; cDNA DKFZp434E033  
1304879 DAPP1—dual adaptor of phosphotyrosine 
1309376 Homo sapiens cDNA FLJ13092 fis, clone 
1349857 IARS—isoleucine-Trna synthetase 
1402715 ESDN—endothelial and smooth muscle ce 
142949 STK17B—serine/threonine kinase 17b (a 
1453049 SCNN1A—sodium channel, nonvoltage-gat 
1481225 ADD3—adducin 3 (gamma) 
1506093 GOLGB1—golgi autoantigen, golgin subf 
157510 CHI3L1—chitinase 3-like 1 (cartilage 
1611623 PLSCR1—phospholipid scramblase 1 
1624206 PRP17—pre-mRNA splicing factor 17 
1648517 ATP12—homolog of yeast ATP12 
1662893 C18orf1—chromosome 18 open reading fr 
1674405 ABCE1—ATP-binding cassette, sub-famil 
1690295 potassium voltage-gated channel, subfa 
1711594 HNF3A—hepatocyte nuclear factor 3, al 
1722870 NXF1—nuclear RNA export factor 1 
1724982 TP53BP1—tumor protein p53 binding pro 
1793853 ALCAM—activated leucocyte cell adhesi 
1796576 calcium channel, voltage-dependent, L 
1803418 KIAA0089—KIAA0089 protein 
1808121 KIAA1324—KIAA1324 protein 
1809315 NISCH—nischarin 
1813269 CES1—carboylesterase 1 (monocyte/mac 
1822809 Homo sapiens mRNA; cDNA DKFZp762M127  
1844691 ALE2—armadillo repeat protein ALE2 
1850249 Homo sapiens cDNA FLJ11375 fis, clone 
1879041 MYBL1—v-myb myeloblastosis viral onco 
1967307 CG005—hypothetical protein from BCRA2 
1968576 FBP1—fructose-1,6-bisphosphatase 1 
1985366 PPP1CA—protein phosphatase 1, catalyt 
1998792 P28—dynein, aonemal, light intermedi 
2007691 STK15—serine/threonine kinase 15 
2013673 CTNS—cystinosis, nephropathic 
2045455 C20orf12—chromosome 20 open reading f 
2057823 E2-EPF—ubiquitin carrier protein 
2133608 TTK—TTK protein kinase 





 2242817 Homo sapiens, clone MGC:22588 IMAGE:46 
2285109 Homo sapiens, Similar to RIKEN cDNA 17 
2288855 microtubule-associated protein tau 
2366522 MGC4251—hypothetical protein MGC4251 
2414624 MAD2L1—MAD2 mitotic arrest deficient- 
2444942 CENPA—centromere protein A (17Kd) 
2498968 KIAA0753—KIAA0753 gene product 
2500225 Homo sapiens clone 24405 mRNA sequence 
2555590 v-myb avian myeloblastosis viral oncog 
2590131 CD3G antigen, gamma polypeptide (TiT3 
2608629 cytochrome P450, subfamily IA (stero 
2716261 Homo sapiens cDNA FLJ20115 fis, clone 
2740235 CDKN2A—cyclin-dependent kinase inhibi 
2791936 TRIM28—tripartite motif-containing 28 
2833929 ESTs 
2875922 Homo sapiens, clone IMAGE:3448367, Mrn 
3123244 Human clone 23948 mRNA sequence 
3127171 Human glucocorticoid receptor alpha Mr 
3242480 DLG5—discs, large (Drosophila) homolo 
3251982 PTPRT—protein tyrosine phosphatase, r 
3279439 GOSR2—golgi SNAP receptor comple mem 
3451473 ESTs 
3970665 microseminoprotein, beta- 
447148 Homo sapiens cDNA: FLJ23005 fis, clone 
515453 KRAS2—v-Ki-ras2 Kirsten rat sarcoma 2 
553251 QDPR—quinoid dihydropteridine reducta 
644989 RERG—RAS-like, estrogen-regulated, gr 
690231 SCYA18—small inducible cytokine subfa 
740878 DUSP4—dual specificity phosphatase 4 
88935 Incyte EST 





























Table 3.3: List of 10 gene signature 
 
Clone ID Gene Name MAP 
1722870 NXF1—nuclear RNA export factor 1 11q12-q13 
1822809 Homo sapiens mRNA; cDNA DKFZp762M127 11 
1998792 P28—dynein, aonemal, light intermedi 1p35.1 
2190664 KIAA0882—KIAA0882 protein 4q31.1 
2555590 v-myb avian myeloblastosis viral oncog 6q22-q23 
2740235 CDKN2A—cyclin-dependent kinase inhibi 9p21 
3123244 Human clone 23948 mRNA sequence 15q22.32 
644989 RERG—RAS-like, estrogen-regulated, gr 12p13.1 
690231 SCYA18—small inducible cytokine subfa 17q11.2 
2007691 STK15—serine/threonine kinase 15 20q13.2-q13.3
The classification accuracy of this set of genes was determined using the Naïve Bayes 
algorithm in WEKA with leave-one-out cross validation. This algorithm generated a 
classification accuracy of 79.55%. The percentage of correctly classified aGS was 71.43%, dGS 
was 64.29%, and aGU was 100%.  The results of the multi-classification are graphically 
represented in Figure 3.1.  
Thus the resulting two largely concordant signatures from both the approaches confirmed 
the relevance of the identified signature genes as descriptors of genomic instability. These two 
signatures (that had 5 genes in common) were combined resulting in the 12-gene genomic 
instability signature list. Among the 12-gene genomic instability signature, SCYA18, STK15 and 
CDKN2A were over expressed in genomically unstable breast carcinomas, while the remaining 
genes were under expressed in genomically unstable tumors (p < 0.001, two sided t-tests). This 
gene signature was then used to predict breast cancer outcomes in previously published 






Table 3.4: List of 12 gene signature 





sided    
t-test) 
1722870 NXF1—nuclear RNA export factor 1                           Under Expressed 0.001154 
1822809 Homo sapiens mRNA; cDNA DKFZp762M127 Under Expressed 1.11E-05 
1998792 P28—dynein, aonemal, light intermedi Under Expressed 2.12E-06 
2190664 KIAA0882—KIAA0882 protein Under Expressed 6.13E-08 
2555590 v-myb avian myeloblastosis viral oncog Under Expressed 5.07E-06 
2740235 CDKN2A—cyclin-dependent kinase inhibit Over Expressed 0.000116 
3123244 Human clone 23948 mRNA sequence Under Expressed 1.05E-05 
644989 RERG—RAS-like, estrogen-regulated, gr Under Expressed 9.56E-07 
690231 SCYA18—small inducible cytokine subfa Over Expressed 9.85E-05 
2007691 STK15—serine/threonine kinase 15 Over Expressed 2.48E-08 
171194 HNF3A—hepatocyte nuclear factor 3, al Under Expressed 7.42E-05 
88935 Incyte EST Under Expressed 8.28E-05 
 
 
The classification accuracy of the 12-gene signature in classifying 44 breast cancer 
tumors into genomic stability (GS) and genomic unstability (aGU) was determined using the 
Naïve Bayes algorithm in WEKA with leave-one-out cross validation. This algorithm generated 
a classification accuracy of 97.73%. The percentage of correctly classified GS was 96.43% and 
aGU was 100%. This accuracy was higher than that generated individually by the 7-gene 
signature and the 10-gene signature, thereby confirming the improvement in the performance of 
the combined gene signatures over the individual gene signatures. The confusion matrix 
generated as a result of the classification is as shown below in Table 3.5. 
Table 3.5: Classification accuracy of 12-gene signature 
Classified as => GS aGU Accuracy for each class
GS 27 1 96.43% 
aGU 0 16 100% 





The 12-gene signature was further subjected to unsupervised validation by performing a 
hierarchical clustering analysis with CIMminer (45), to group 44 breast carcinomas. The gene 
expression was aggregated based on Euclidean distance with average linkage.  The distance of 
the samples was computed based on correlation and the cluster method was complete linkage. 
The cluster analysis as shown in Figure 3.2, represents the aggregation into two groups 
separating genomically stable (dGS and aGS) from unstable tumors (aGU).  It confirms a linkage 
between the degree of genomic instability and gene-expression patterns. 
 
Figure 3.2: Hierarchical clustering analyses with CIMminer performed on 44 breast carcinomas 











This study sought to explore the extent to which the gene expression signature (that defines 
genomic instability in the breast cancer) could be used for prediction of disease outcome in 
previously published independent datasets.  
Various classification algorithms were tried in WEKA using a leave-one-out cross 
validation technique to classify the samples in each of the datasets. The samples in each of the 
datasets were first stratified into low risk and high risk depending on the survival information 
and status of the clinical outcome. The criteria that were considered for the stratification were:  
RFS ≤ 5 years and Status =1 ‐  High risk   
RFS > 5 years and Status = 0 ‐  Low risk 
The classification algorithms in WEKA were used to obtain the classification accuracy. 
Since the datasets were generated on diverse microarray platforms and had incompatible 
expression profiles, the classification algorithms in WEKA failed to give consistent results 
across the datasets. A single classification model could not be used across all the datasets. 
Moreover, the results of these classification algorithms gave an estimate over a specific period of 
5 years. The need to analyze the clinical outcomes over the time-course was identified which was 
possible by Kaplan-Meier survival curves. The results obtained by performing a leave-one-out 







Table 3.6: Classification analyses using various classification algorithms in WEKA          
   
































































Naïve Bayes 62.05 74.71 66.8 68.38 100 0 57.95 50 36.36 82.35 71.11 59.36 
Neural 
Network 
77.51 54.02 69.53 65.77 68.63 56.76 63.64 62.7 36.36 85.29 73.33 60.83 
IBk 72.78 41.38 62.11 57.08 58.82 56.76 57.95 57.79 36.36 85.29 73.33 60.83 
Random 
Committee 
81.66 22.99 61.72 52.33 82.35 40.54 64.77 61.45 18.18 94.12 75.56 47.15 
HyperPipes 95.86 9.2 66.41 52.53 86.27 13.51 55.68 49.89   0 91.18 68.89 45.59 
Random 
Forest 
81.66 28.74 63.67 55.2 72.55 40.54 59.09 56.55 36.36 91.18 77.78 63.77 
Decision 
Table 
62.72 74.71 66.8 68.72 100 0 57.95 50   0 91.18 68.89 45.59 
Average 76.32 43.68 65.29 60.00 81.23 29.73 59.58 55.48 23.37 88.66 72.7 54.73 
Considering the inconsistent results of the above analyses and the need for a single 
classification algorithm, the nearest centroid classification method was adopted for evaluating 
the accuracy of the identified 12-gene genomic instability signature on other datasets used for 
validation. The accuracy of the gene signature was evaluated on 496 tumor profiles in breast 
cancer that were obtained from the published datasets:  
Matchminer (46) was used to obtain the gene names for  those genes that had either clone 
id or affymetrix id as a gene-identifier in the validation datasets. The genes in the signature were 
identified in each of the datasets used for validation. The average gene expression of each gene 





the training dataset and was considered as a standardized centroid. Each patient in the validation 
cohorts was classified into GS group or aGU group based on the Pearson correlation of the 
patient’s gene expression profiles with the average expression profiles (centroids) of the GS and 
aGU group in the training data.  Table 3.7 contains the gene expression centroids obtained for 
each gene in each of the two groups.  
Table 3.7: Average gene expression profiles (centroids) for 12 genes 
Gene names aGU  GS 
CDKN2A--cyclin-dependent kinase 
inhibi  
1.06749 0.046581  
HNF3A--hepatocyte nuclear factor 3, 
al  
-0.46792 1.393824  
Homo sapiens mRNA; cDNA 
DKFZp762M127  
-0.70024 0.119753  
Human clone 23948 mRNA sequence 0.940516 2.622091  
Incyte EST  0.061511 0.55565  
KIAA0882--KIAA0882 protein  -0.49695 0.955434  
NXF1--nuclear RNA export factor 1 0.015858 0.639736  
P28--dynein, axonemal, light 
intermedi  
0.199474 1.202058  
RERG--RAS-like, estrogen-
regulated, gr  
-0.30429 0.925177  
SCYA18--small inducible cytokine 
subfa  
2.343289 0.710686  
STK15--serine/threonine kinase 15  -1.04827 -1.90629  
v-myb avian myeloblastosis viral 
oncog  






In the external validation, patients were classified as GS (genomically stable) if the 
correlation of the gene expression with the average GS centroid was higher than that with the 
average aGU centroid. Similarly, patients were classified as aGU (genomically unstable) if the 
correlation of the gene expression with the average aGU centroid was higher than that with the 
average GS centroid. If there were multiple probes for the same annotated gene, the average of 
the gene expressions was computed for all the probes and used in the correlation analysis. In 
order to compare the performance with other signatures, no threshold was set on correlation 
coefficients in patient classification and no patient was removed. Thus, using the nearest centroid 
classification algorithm, the patients in each validation cohort were classified to the group with 
the centroid, to which the gene expression profile of the new sample was closest to in squared 
distance16. The distribution of the correlation coefficients for each validation dataset is as shown 










































Figure 3.5: Correlation coefficients with the GS and aGU centroids in patients from Van de 









To test the statistical significance of this classification, Kaplan-Meier analysis was 
performed. For each validation dataset, the predictive class that was obtained from the nearest 
centroid classification was taken and survival curves were plotted using the survival package in 
R (33). Statistical significance of the difference between the survival curves for different 
prognostic groups was assessed using likelihood ratio tests and log-rank tests.  
Kaplan-Meier analyses showed that genomic instability-defined prognostic groups were 
associated with distinct relapse-free and overall survival (p < 0.05, log-rank tests) despite the 
fact that about 50% of the patients died without having suffered from breast cancer recurrence 
(8). Patients with GS signature had longer relapse-free survival and overall survival than those 








Figure 3.6: The 12-gene signature classifies breast cancer patients from Sotiriou’s cohort into 
prognostic subgroups with distinct relapse-free survival and overall survival in Kaplan-Meier 
analysis (p <0.05, log-rank test). The curves in red represent the genomically stable group and 














Figure 3.7: The 12-gene signature classifies breast cancer patients from Sorlie’s cohort into 
prognostic subgroups with distinct relapse-free survival and overall survival in Kaplan-Meier 
analysis (p <0.05, log-rank test). The curves in red represent the genomically stable group and 
the curves in green represent the genomic instability group. 
 
Figure 3.8: The 12-gene signature classifies breast cancer patients from van de Vijver’s cohort 
into prognostic subgroups with distinct relapse-free survival, overall survival in Kaplan-Meier 
analysis (p <0.05, log-rank test). The curves in red represent the genomically stable group and 









In this study, the association between genomic instability-defined risk groups and traditional 
prognostic factors of breast cancer was evaluated by combining all the validation datasets 
together and performing either Pearson’s Chi-squared test or Fisher’s exact test (two-sided) 
between the genomic instability-defined risk groups and each of the traditional (clinical) factors 
such as lymph node status, tumor grade, estrogen receptor status, and age. Chi-squared test was 
performed using the ‘chisq.test’ function in R (33).  Chi-squared test was used if its assumptions 
were satisfied.  Otherwise, Fisher’s exact test was applied using the R function ‘fisher.test’ (33).  
Table 3.8 reports the p values resulted from the tests. A p < 0.05 indicates a significant 
association between the genomic instability signature and the corresponding clinical-pathological 
parameter. Thus, from Table 3.8, the risk groups defined by the 12-gene genomic instability 












Table 3.8: Association between the 12-gene genomic instability signature and clinic-
pathologic parameters in patients (n=469) combined from Sorlie’s cohort (n=75), Sotiriou’s 




 GS Group aGU Group p-value 
Age 
    ≤53  






  71/316 
 
118/153 
  35/153 
 
p < 0.98 
Lymph Node 
Status 
   Positive 








  77/153 




   Positive 
   Negative 







  25/316 
    2/316 
 
  58/153 
  95/153 
 
 
p < 2.2e-16 
Tumor Grade 
    I  
    II 
    III 







  22/114 
  53/114 
  38/114 
    1/114 
 
      3/60 
    18/60 




Having studied the association, we were curious to investigate whether the 12-gene 
genomic instability signature could further stratify patients belonging to certain subgroups into 
genomic instability-defined prognostic risk groups. This was achieved by first, combining 
together patients having the same subgroup of clinical parameters (such as lymph node-positive, 
lymph node-negative, tumor grade II, NIH high risk, and St.Gallen high risk) from the three 
validation datasets, and then plotting Kaplan-Meier survival curves by using the predictive class  
obtained from the nearest centroid method. These survival curves depicted the statistical 





3.5.1.  The  12­gene  signature  is  independent  of  lymph  node  status  in  breast  cancer 
prognosis  
 
To investigate whether the 12-gene signature was independent of lymph node status, the three 
validation cohorts were combined and the lymph node-negative patients and lymph node-
positive patients were analyzed separately. For lymph node-positive patients, the GS and the 
aGU groups had distinct disease-free survival (log-rank tests; p=0.001; n=249; Figure 3.9A) and 
distinct overall survival (log-rank test; p<0.0001; n=249; Figure 3.9B). For lymph node-negative 
patients, the GS and the aGU groups had distinct disease-free survival (log-rank tests; p=0.0002; 
n=220; Figure 3.9C) and distinct overall survival (log-rank test; p<0.0001; n=220; Figure 3.9 D). 
It was seen that the 12-gene signature quantified breast cancer outcomes in Kaplan-Meier 
analyses independent of lymph node status in a combination of the three patient cohorts. Thus 
the 12-gene genomic instability signature could provide additional prognostic information within 
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Figure 3.9: The 12-gene signature stratifies patients with lymph node status into subgroups with 
distinct disease-free survival (A and C) and overall survival (B and D) in Kaplan-Meier analysis. 
The curves in red represent the genomically stable group and the curves in green represent the 








In order to investigate whether the 12-gene signature is independent of tumor grade II, we 
combined the three external validation cohorts and analyzed all the patients with tumor grade II. 
The GS and the aGU groups were found to have distinct disease-free survival (log-rank test;     
p<0.0001; n=172; Figure 3.10A) and overall survival (log-rank test; p=0.0001; n=172;          
Figure 3.10B).  It was observed that in grade II tumors, application of the 12-gene signature 
allowed for improved prognostic classification. The results of this analysis are as shown in the 
Figure 3.10. 










Figure 3.10: The 12-gene signature stratifies patients with tumor grade II into subgroups with 
distinct disease-free survival (A) and overall survival (B) in Kaplan-Meier analyses. The curves 
in red represent the genomically stable group and the curves in green represent the genomic 












According to van’t Veer et al.(9), a patient was considered as high-risk by NIH criteria, if the 
tumor size was greater that 1cm, and was considered  high-risk by St.Gallen criteria, if one or 
more of the following conditions were true: estrogen (negative) or tumor size (>2 cm) or tumor 
grade (Grade II or III) or patient age (< 35 years).  This study sought to investigate if the 12-gene 
genomic instability signature could provide additional prognostic information within the high-
risk groups defined by the NIH criteria (42) and the St.Gallen criteria (43). Patients from the 
three cohorts were combined and the ones who were defined high-risk were analyzed for each 
criterion.  
It was found that, among the high-risk patients defined by the NIH criteria (n=377), those 
with the GS signature had significantly better prognosis than those with the aGU signature for 
both disease-free survival (log-rank test; p=0.0001; n=377; Figure 3.11A) and overall survival   
(log-rank test; p<0.0001; n=377; Figure 3.11B). Similarly in the case of high risk patients 
defined by the St.Gallen criteria (n=439), those with the GS signature had significantly better 
prognosis than those with the aGU signature for both disease-free survival (log-rank test; 
p<0.0001; n=439; Figure 3.12A) and overall survival (log-rank tests; p<0.0001; n=439; Figure 
3.12B).  
 It was seen that the 12-gene signature quantified breast cancer outcomes in           
Kaplan-Meier analyses independent of high-risk groups defined by NIH and St.Gallen criteria, in 





provide additional prognostic information within high-risk subgroups defined by NIH and 
St.Gallen criteria. 
  A         B  
 
Figure 3.11: The 12-gene signature stratifies high risk patients defined by NIH Criteria into 
subgroups with distinct disease-free survival (A) and overall survival (B) in Kaplan-Meier 
analyses.  The curves in red represent the genomically stable group and the curves in green 
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Figure 3.12: The 12-gene signature stratifies high risk patients defined by St. Gallen Criteria 
into subgroups with distinct disease-free survival (A) and overall survival (B) in Kaplan-Meier 
analyses.  The curves in red represent the genomically stable group and the curves in green 



















In this chapter, we sought to explore if there is a linkage between the degree of genomic 
instability, gene expression patterns, and clinical outcomes. This was achieved by first, 
identifying a 12-gene genomic instability signature from a training dataset that contained 7657 
genes measured on 48 breast cancer patients with varying degrees of genomic instability.  A 
combination of different feature selection algorithms was employed to identify the 12-gene 
genomic instability signature. By using the nearest centroid classification algorithm, the 12-gene 
genomic instability signature could significantly stratify patients from multiple validation 
datasets, into prognostic groups. The significance of this stratification was tested by Kaplan-
Meier analyses and log-rank tests. It was observed that the gene expression-defined groups had 
distinct relapse-free and overall survival independent of traditional prognostic factors (n=469,    
p < 0.05, log-rank tests).  
Thus the degree of genomic instability which is measured by the nuclear DNA content, 
directly impacts on a breast cancer patient’s prognosis and serves as one of the most powerful 
predictors of clinical outcome independent from established parameters (4;5). Patients with 
breast carcinomas having a relatively stable genome have considerably longer disease-free 
survival times compared to the ones having genomically unstable tumors (2;3). Therefore, 
prognostication based on gene expression signatures could be augmented by the quantitative 











In this study, the importance of selecting patients at high-risk for recurrence for additional 
chemotherapy was realized at the light of the fact that, breast cancer patients with advanced 
stages receive chemotherapy, but only half of them benefit from it (11). The two available gene 
signatures, namely, Oncotype (8) and Mammaprint (9) are based on specific subgroups of breast 
cancer patients. Specifically, Oncotype was designed for tamoxifin-treated, node-negative, 
estrogen receptor-positive breast cancer patients, and Mammaprint was used for lymph node-
negative women under the age of 61 with a tumor size less than 5 cm. A population-based 
approach was needed to the molecular prognosis of breast cancer for predicting breast cancer 
recurrence in broader clinical settings. 
Our previous studies (13)  have shown that breast cancer recurrence and metastases can 
be predicted at the individual level, based on a 28-gene recurrence signature that was developed 
from Sotiriou et al. (34) on a population-based approach.  This dataset contained 7650 genes on 
99 node-negative and node-positive patient samples. In this study, we validated the 28-gene 
expression signature on several independent datasets that had different clinical-pathological 
characteristics and were generated on various DNA microarray platforms. The nearest centroid 
classification algorithm (10) was employed for stratifying the patients from the validation 
datasets into different prognostic groups. The association of the gene signature-defined 





breast cancer disease-free survival and overall survival. The ability of the 28-gene signature to 
further stratify the clinical subgroups was investigated.  
The significance of this work in the clinical management is that, it could enable 
physicians to take proper decisions regarding the need for additional chemotherapy for     
patients (47). They could identify the high-risk patients based on this molecular classification 
scheme. Moreover, this study also sought to investigate if a common gene set could predict a 
poor outcome in breast cancer and ovarian cancer (12). According to epidemiological studies 
(48), breast cancer patients have an increased risk of primary ovarian cancer.  
The remainder of the chapter is organized as follows: Section 4.2 discusses the previous 
work done, related to the development of the 28-gene signature, Section 4.3 elucidates the 
process of validation of the 28-gene signature in multiple DNA microarrays using the nearest 
centroid classification method, Section 4.4 illustrates the association of the gene expression- 
defined risk groups and clinical parameters, Section 4.5 explains the analysis of the 28-gene 




The 28-gene expression signature was previously identified in our lab (13), from Sotiriou et al. 
(34) which comprised of a gene expression data containing 7650 genes assayed by cDNA 
microarray on 99 patient samples, 53 of which were node-positive and 46 of node-negative 









The data was first pre-processed to remove genes that had more than 5 missing values. 
559 genes were eliminated in this step, and the remaining missing values were replaced by using 
the EMV package in software R18. The k-nearest-neighbor algorithm (k=20) was used to 
estimate the missing values. There were 7091 genes in the dataset after data pre-processing. 
The marker genes were identified by using a combination of random forests employing 
the VarSelRF package of software R (33), and linear discriminant analysis (LDA) of software 
SAS19. The VarSelRF package in R (33) was used in a series of steps. In the first step, a forest 
with N trees was built and the features were ranked according to the importance of the variables. 
In the second step, 20% of the variables that were least important were removed and a new forest 
was constructed with K trees. This step was repeated till there were two genes left. The gene 
subset with the smallest OOB error rate was selected.  In the experiments, a value of N = 3000 
and K =1000 were considered, because a large number of trees in the initial forests is likely to 
produce stable importance measures (19). The “0-Standard Error (0-SE) rule” was observed that 
identifies the gene subset with the smallest OOB error rate. The 28-gene signature that was 














Table 4.1:  List of 28-gene signature 
Gene Spot ID Clone ID  UniGene Cluster ID 
Homo sapiens GT212 
mRNA  3912 198917  Hs.463079 
TOMM70A 4919 198312  Hs.227253 
MCF2 2370 268412  Hs.387262 
RAD52 homolog 418 1377154  Hs.552577 
MCM2 1881 239799  Hs.477481 
C18B11 5984 131988  Hs.173311 
SEC13L 6497 757210  Hs.301048 
SLC25A5 5182 291660  Hs.522767 
PLSCR1 6959 268736  Hs.130759 
TXNRD1 7296 789376  Hs.434367 
RAD50 2925 261828  Hs.242635 
- 6498 46196  
INPPL1 1987 703964  Hs.523875 
- 583 501651  Hs.439445 
TXNRD1 6736 789376  Hs.434367 
PBX2 536 80549  Hs.509545 
SSBP1 3434 125183  Hs.490394 
HSPCB (heat shock 
90kD protein 1, beta) 2403 34396  Hs.448229 
PDGFRA 6674 376499  Hs.74615 
ACOT4 6555 488202  Hs.49433 
DDOST 2416 50666  Hs.523145 
Immunoglobulin alpha 
(1 or 2) heavy chain 
constant region 2276 182930  Hs.497723 
S100P 5593 135221  Hs.2962 
FAT 7009 591266  Hs.481371 
FGF2 3514 324383  Hs.284244 
INSM1 3061 22895  Hs.89584 
IRF5 5962 260035  Hs.521181 
SMARCD2 2923 741067  Hs.250581 








The predictive power of the 28 genes was investigated in assessing breast cancer outcomes. We 
designed a prognostic categorization scheme for DNA microarray datasets that were generated 
on various platforms. We adopted the nearest centroid classification method for estimating the 
predictive power of the identified gene signature on other datasets that were used for validation. 
These datasets contained various DNA microarray platforms such as DNA microarrays, 
Affymetrix U95, U133A, and U133 plus 2.0. The examined outcomes include relapse-free 
survival (RFS), metastases-free survival (MFS), disease-free survival (DFS; where a clinical 
event refers to either a local recurrence or distant metastases of breast cancer), disease-specific 
survival (DSS; an event refers to death from breast cancer), and overall survival (OS). The 
previously published datasets used for validation in this experiment were: 
1) Bild et al. (38) (PMID: 16273092) - This cohort contained a total of 157 patients; 110 with 
estrogen receptor (ER)-level 1, and 47 with ER-level 0. The dataset is publically available at the 
Gene Expression Omnibus database with an accession number GSE3143.         
2) Sorlie et al. (36) (PMID: 12829800) - This cohort contained a total of 122 tissue samples of 
which, 77 carcinomas and 7 nonmalignant tissues were previously published. There were 83 ER-
positive patients and 32 ER-negative patients. There were 34 lymph node-negative patients and 
46 lymph node-positive patients. The cohort contains 11 patients with Grade I, 49 patients with 
Grade II, and 53 patients with Grade III. The dataset is publically available at the Gene 
Expression Omnibus database with an accession number GSE4335. 
3) Wang et al. (37) (PMID: 15721472) - This cohort contained 286 lymph node-negative patients 





ER-positive and 77 ER-negative patients. There were 165 progesterone receptor (PR)-positive, 
111 PR-negative and 10 with unknown PR status. 148 patients had poor grade, 42 had moderate 
grade, 7 had good grade, and 89 had unknown grade. There were 139 pre-menopausal and 147 
post-menopausal patients. The dataset is publically available at the Gene Expression Omnibus 
database with an accession number GSE2034. 
4) Van de Vijver et al. (10) (PMID: 12490681) - There were a total of 295 consecutive patients 
with primary breast carcinomas; 151 with lymph node-negative disease, and 144 with lymph 
node-positive disease. The dataset is publically available at the Rosetta Inpharmatics website20.  
5) Miller et al. (39) (PMID: 16141321) - This cohort contained a total of 236 patients; 62 patients 
with Grade I, 121 with Grade II, 51 with Grade III and 2 patients with unknown grade 
information. 201 patients were ER-positive and 31 patients were ER-negative. There were 179 
PR-positive patients and 57 PR-negative patients.  The cohort contained 78 lymph node-positive 
patients and 149 lymph node-negative patients. The dataset is publically available at the Gene 
Expression Omnibus database with an accession number GSE3494.     
6) Loi et al. (41) (PMID: 17401012) - This cohort contained 137 untreated patients and 277 
tamoxifen treated patients. Gene expression profiles of 327 patients were screened on GPL96 
Affymetrix Gene Chip Human Genome U133 Array Set HG-U133A platform and 87 patient 
expression profiles were generated on GPL570 Affymetrix GeneChip Human Genome U133 
plus 2.0 Array. The cohort contained 250 lymph node-negative patients and 143 lymph node- 
positive patients. There were 82 patients with Grade I, 182 patients with Grade II, and 76 







dataset is publically available at the Gene Expression Omnibus database with an accession 
number GSE6532.    
7) Ivshina et al. (40) (PMID: 17079448) - This cohort contained patient and tumor samples of the 
Uppsala and Singapore sets. The Uppsala set was composed of 249 patients. The Singapore set 
contained 40 patients. There were 211 ER-positive patients and 34 ER-negative patients.  This 
cohort contained 81 lymph node-positive patients and 159 lymph node-negative patients. The 
dataset is publically available at the Gene Expression Omnibus database with an accession 
number GSE4922.      
Various classification algorithms were tried in WEKA using a leave-one-out cross 
validation technique to classify the samples in each of the datasets. The samples in each of the 
datasets were first stratified into low risk and high risk depending on the survival information 
and status of the clinical outcome. The criteria that was considered for the stratification were  
RFS ≤ 5 years and Status =1 ‐  High risk   
RFS > 5 years and Status = 0 -> Low risk 
The classification algorithms in WEKA were used to obtain the classification accuracy. A 
cross-cohort validation was also performed by considering datasets from the same platform 
namely, Wang et al.(37), Ivshina et al. (40), and Loi et al. (41). The best classification model was 
identified in WEKA by performing a 10-fold cross validation on Wang et al. (37). Logistic was 
found to be the classification algorithm that produced the highest classification accuracy. This 
model was applied to the testing datasets, Ivshina et al.(40) and Loi et al.(41). It was found that 





results of the classification accuracies generated in the cross-cohort validation analyses are 
shown in Table 4.2. 
Table 4.2: Results of cross-cohort validation using Logistic algorithm in WEKA  
 
Dataset Sensitivity Specificity Overall 
Accuracy 
(Sensitivity+Specificity)/2
Wang 43.16 82.74 68.44 62.95 
Ivshina(Testing) 0 100 66.5 50 
Loi(Testing) 0 100 64.86 50 
Since the datasets were generated on diverse microarray platforms and had incompatible 
expression profiles, the classification algorithms in WEKA failed to give consistent results 
across the datasets. A single classification model could not be used across all the datasets. 
Moreover, the results of these classification algorithms gave an estimate over a specific period of 
5 years. The need to analyze the clinical outcomes over the time-course was identified which was 
possible by Kaplan-Meier survival curves. The results obtained by performing a leave-one-out 











Table 4.3: Classification analyses using various classification algorithms in WEKA          
    



































































77.51 51.72 68.75 64.62 63.1 62.11 62.74 62.61 92.41 0 74.87 46.2 
Neural 
Network 
75.74 41.38 64.06 58.56 64.88 45.26 57.79 55.07 82.28 21.62 70.77 51.95 
IBk 76.33 37.93 63.28 57.13 77.98 31.58 61.22 54.78 88.6 16.22 74.87 52.41 
Random 
Committee 
89.35 29.89 69.14 59.62 89.29 18.95 63.88 54.12 99.37 5.4 81.54 52.39 
Hyperpipes 95.86 5.75 65.23 50.81 91.07 10.53 61.98 50.8 99.37 0 80.51 49.68 
Random 
Forest 
85.8 36.78 69.14 61.3 85.12 18.95 61.22 52.04 98.10 5.41 80.51 51.76 
Decision 
Table 
76.33 32.18 61.33 54.26 99.4 0 63.5 49.7 92.41 0 74.87 46.2 
Average 82.42 33.66 65.84 58.04 81.55 26.77 61.76 54.16 93.22 6.95 76.85 50.08 
Thus, considering the inconsistent results of the above analyses and the need for a single 
classification algorithm, the nearest centroid classification method was adopted for evaluating 
the accuracy 28-gene signature on other datasets used for validation. In the process of validation, 
the patients in the training dataset from Sotiriou et al. (34) were classified into two subgroups, 
namely, good-prognosis and poor-prognosis based on their survival information which included 
relapse-free survival, and status (that indicates if the patient developed metastases or not). A 
patient was classified into good-prognosis group if the patient survived longer than five years 
after the primary treatment; otherwise, the patient was classified into poor-prognosis group. The 
criteria used for the classification is expressed as: 





        RFS < 5 years, Status =1    →    poor-prognosis 
The average expression centroids (profiles) of the patients with good-prognosis and poor- 
prognosis were computed separately in the training dataset from Sotiriou et al. (34).  Table 4.4 
contains the gene expression centroids obtained for each gene in each of the two groups.  
Table 4.4:  Gene Expression profiles (centroids) of 28 genes 
GENE  Poor  prognosis  Good  prognosis  
C18B11  -0.00243  -0.08241  
DDOST  -0.36212  -0.625  
FAT  0.331797  0.243982  
FGF2  -0.14305  -0.04102  
Immunoglobulin alpha (1 or 2) 
heavy chain constant region 
0.823265  1.205533  
Homo sapiens GT212 mRNA 0.496081  0.678341  
HSPCB (heat shock 90kD protein 
1, beta) 
-0.59895  -0.77243  
IMAGE:46196  -0.38726  -0.53131  
ACOT4 0.480262  0.592882  
IMAGE:501651  0.149646  0.291806  
INPPL1  0.397124  0.541886  
INSM1  0.285381  0.367837  
IRF5  -0.31068  -0.50189  
MAP2K2  -0.06515  0.007757  
MCF2  0.1877  0.258102  
MCM2  -1.25522  -1.46739  
PBX2  -0.17896  -0.2586  
PDGFRA  0.10173  0.203139  
PLSCR1  0.173373  -0.12427  
RAD50  0.182354  0.258133  
RAD52 homolog  0.085389  0.189869  
S100P  0.2262  -0.55354  
SEC13L  -0.84496  -1.28998  
SLC25A5  -0.7837  -1.2255  
SMARCD2  0.127054  0.236324  
SSBP1  -0.48885  -0.68036  
TOMM70A  0.232762  0.112048  





Each patient in the validation cohorts was categorized into good-prognosis group or poor-
prognosis group based on the Pearson correlation of the patient’s gene expression profiles with 
the average expression profiles of the good-prognosis centroid in the training set. If there were 
multiple probes for the same annotated gene, the average of the gene expressions for all the 
probes was computed and used in the correlation analysis. As the validation sets contain DNA 
microarrays that were generated on heterogeneous platforms, different cut-off values were 
chosen for patient stratification based on the correlation coefficients with the average good-
prognosis centroid.  A patient was classified as good-prognosis if the correlation was greater than 
the corresponding cut-off value; otherwise, this patient was classified as poor- prognosis.  
A cut-off value of -0.3 was taken for predicting overall survival (OS) and disease-specific 
survival (DSS). This cut-off value was applied consistently in patient stratification for three 
different platforms: Affymetrix HG-133A [Miller et al. (39)], Affymetrix HG-U95 [Bild et al. 
(38)]. For relapse-free survival and disease-free survival prediction, several cut-off values were 
chosen for different platforms as follows: A cut-off value of 0.15 was considered for cDNA 
microarrays [van de Vijver et al.(10) and Sorlie et al.(36)],  -0.4 for Affymetrix HG-U133A 
[Wang et al.(37) , Ivshina et al.(40), and Loi et al.(41)], and -0.5 for Affymetrix U133 Plus 2.0 
Array [Loi et al. (41)]. The different cut-offs taken for different platforms and clinical endpoint 









Table 4.5:  Table of various cut-offs taken for various platforms 
  
 
Platform cDNA  
microarray 











           0.15             -0.4        -0.3  -0.3 -0.5 
Datasets Van de 
Vijver 
















The significance of this stratification scheme was tested by Kaplan-Meier analyses and 
log-rank tests. For each validation dataset, the predictive class obtained from the nearest centroid 
classification was taken and survival curves were plotted using Kaplan-Meier analyses. Kaplan-
Meier analyses showed that gene expression-defined groups had distinct relapse-free and overall 
survival (p < 0.05, log-rank tests).  The patients belonging to good-prognosis group had higher 
survival probabilities than those belonging to the poor-prognosis groups. 












Figure 4.1:  The 28-gene signature classifies breast cancer patients from van de Vijver’s cohort 
into prognostic subgroups with distinct relapse-free survival and overall survival in Kaplan-
Meier analysis by taking 0.15 as a cut-off for stratifying patients into each subgroup. The cut-off 
is based on the correlation coefficients with the average good-prognosis centroid in the training 












Figure 4.2: The 28-gene signature classifies breast cancer patients from Sorlie’s cohort into 
prognostic subgroups with distinct relapse-free survival and overall survival in Kaplan-Meier 
analysis by taking 0.15 as a cut-off for stratifying patients into each subgroup. The cut-off is 
based on the correlation coefficients with the average good-prognosis centroid in the training set. 















Figure 4.3:  The 28-gene signature classifies breast cancer patients from Wang’s cohort into 
prognostic subgroups with distinct relapse-free survival in Kaplan-Meier analysis by taking -0.4 
as a cut-off for stratifying patients into each subgroup.   The cut-off is based on the correlation 
coefficients with the average good-prognosis centroid in the training set. The curves in red 












Figure 4.4:  The 28-gene signature classifies breast cancer patients from Ivshina’s cohort into 
prognostic subgroups with distinct disease-free survival in Kaplan-Meier analysis by taking -0.4 
as a cut-off for stratifying patients into each subgroup.  The cut-off is based on the correlation 
coefficients with the average good-prognosis centroid in the training set. The curves in red 








Figure 4.5:  The 28-gene signature classifies breast cancer patients from Loi’s cohort into 
prognostic subgroups with distinct relapse-free survival in Kaplan-Meier analysis by taking -0.4 
as a cut-off for GPL 96 and -0.5 as a cut-off for GPL 570. The cut-off is based on the correlation 
coefficients with the average good-prognosis centroid in the training set. The curves in red 












Figure 4.6:  The 28-gene signature classifies breast cancer patients from Miller’s cohort into 
prognostic subgroups with distinct overall survival in Kaplan-Meier analysis by taking -0.3 as a 
cut-off for stratifying patients into each subgroup.  The cut-off is based on the correlation 
coefficients with the average good-prognosis centroid in the training set. The curves in red 
















Figure 4.7: The 28-gene signature classifies breast cancer patients from Bild’s cohort into 
prognostic subgroups with distinct overall survival in Kaplan-Meier analysis by taking -0.3 as a 
cut-off for stratifying patients into each subgroup. The cut-off is based on the correlation coefficients 
with the average good-prognosis centroid. The curves in red represent the good- prognosis group and the 





















In this study, the association between prognostic groups and clinical-pathological parameters was 
determined on the validation datasets by using either Pearson’s Chi-squared test or Fisher’s exact 
test (two-sided) between the two parameters. Chi-squared test was performed using the 
“chisq.test” function in R. Chi-squared test was used if its assumptions were satisfied.  
Otherwise, Fisher’s exact test was applied using the R function “fisher.test”. The clinical 
parameters analyzed in this study were lymph node status, estrogen receptor (ER) status, age, 
and tumor grade. Patient data with disease-free survival information was combined from Van de 
Vijver’s cohort (n=295), Sorlie’s cohort (n=114), Wang’s cohort (n=286), Ivshina’s cohort 
(n=249), Loi’s cohort (n=393). Patient data with overall survival information was combined 
from Van de Vijver’s cohort (n=295), Sorlie’s cohort (n=117), Miller’s cohort (n=236), Bild’s 
cohort (n=158). 
Table 4.6 and Table 4.7 report the p values resulting from the tests for datasets with 
disease-free survival information and overall survival information respectively. A p<0.05 
indicates a significant association between the gene expression signature and the corresponding 
clinical-pathological parameter. It was observed that the prognostic groups defined by the        
28-gene expression signature were significantly associated with all the clinical parameters in 
relapse-free survival prediction (p<0.05). In case of overall survival prediction, the prognostic 
groups were significantly associated with ER status and tumor grade (p<0.05) but were not 






Table 4.6: Association between the 28-gene signature and clinic pathologic parameters in 
patients with disease-free survival (n=1337) 
 
  






  <=50  (n=430) 
  >50   (n=621) 
  Unknown (n=286) 








  28/684 
 
0.019 
Lymph Node Status 
   Positive(n=444) 
   Negative(n=870) 












   Positive(n=1075) 
   Negative(n=248) 
   Unknown(n=14) 
 
549/653    
  98/653 








    I (n=168) 
    II(n=327) 
    III(n=245) 
   Unknown(n=597) 
 
  88/653 
124/653 
  41/653 
400/653 
 















Table 4.7: Association between the 28-gene signature and clinic pathologic parameters in 
patients with overall survival (n= 806) 
 







<=50  (n=300) 












Lymph Node Status 
   Positive(n=300) 
   Negative(n=334) 
   Unknown(n=172) 













   Negative(n=179) 
   Positive(n=618) 
















    I (n=148) 
    II(n=270) 
    III(n=223) 
   Unknown(n=165)  







  66/505 
153/505 
180/505 
  71/505 




We sought to investigate whether the 28-gene signature could further refine the 
subgroups defined by these clinical parameters. Patients with available clinical parameters and 
outcomes from all the cohorts were considered in this analysis. For analyzing each clinical 
parameter, patients having the same subgroup of clinical parameters were combined together 





prognostic categorization obtained from the 28-gene signature. These survival curves depicted 
the statistical significance of the gene expression-defined prognostic risk groups.  
4.4.1  The  28­gene  signature  is  independent  of  lymph  node  status  in  breast  cancer 
prognosis. 
 
In order to investigate whether the 28-gene signature is independent of lypmh node status, 
patients from all the external validation cohorts were combined and the lymph node-positive and 
lypmh node-negative patients were analyzed separately. The results of this analysis are shown in 
Figure 4.8. For lymph node-positive patients, the prognostic groups had distinct disease-free 
survival (log-rank test; p<0.0001; n=444; Figure 4.8A) and distinct overall survival (log-rank 
test; p=0.0008; n=300; Figure 4.8B). For lymph node-negative patients, the prognostic groups 
had distinct disease-free survival (log-rank test; p=0.0029; n=870; Figure 4.8C) and distinct 
overall survival (log-rank test; p=0.0001; n=334; Figure 4.8D). It was seen that the 28-gene 
signature quantified breast cancer outcomes in Kaplan-Meier analyses independent of lymph 











A                          B
   
          
C                                                D      
    
Figure 4.8: The 28-gene signature stratified subgroups defined by lymph node status in 
predicting breast cancer disease-free survival (A and C) and overall survival (B and D) using 
Kaplan-Meier analysis. The curves in red represent the good-prognosis group and the curves in 
green represent the poor-prognosis group. 





4.4.2  The 28­gene  signature  is  independent of     estrogen  receptor  (ER)  status    in breast 
cancer prognosis 
 
In order to investigate whether the 28-gene signature is independent of ER status, the patients 
from all the external validation cohorts were combined and the ER-positive and ER-negative 
patients were analyzed separately. The results of this analysis is shown in Figure 4.9. For ER-
positive patients, the prognostic groups had distinct disease-free survival (log-rank test; 
p<0.0001; n=1075; Figure 4.9A) and overall survival (log-rank test; p<0.0001; n=618; Figure 
4.9B). For ER-negative patients, the prognostic groups had distinct disease-free survival (log 
rank test; p=0.0062; n=248; Figure 4.9C) and overall survival (log-rank test; p=0.06; n=179; 
Figure 4.9D).  It was seen that the 28-gene signature quantified breast cancer outcomes in 
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C                 D     
      
Figure 4.9: The 28-gene signature stratified subgroups defined by ER status in predicting breast 
cancer disease-free survival (A and C) and overall survival (B and D) using Kaplan-Meier 
analysis. The curves in red represent the good-prognosis group and the curves in green represent 









In order to investigate whether the 28-gene signature could further stratify patients with tumor 
grade II, the patients from all the external validation cohorts were combined and the patients 
having tumor grade II were analyzed. The results of this analysis is shown below in Figure 4.10. 
It was found that the prognostic groups had distinct disease-free survival (log-rank test;             
p=0.0197; n=327; Figure 4.10A) and overall survival (log-rank test; p=0.0024; n=270;        
Figure 4.10B). It was seen that the 28-gene signature quantified breast cancer outcomes in 
Kaplan-Meier analyses independent of tumor grade II in the combination of different patient 
cohorts.                
A            B
           
 
igure 4.10: The 28-gene signature stratified subgroups defined by Tumor grade II in predicting 
reast cancer disease-free survival (A) and overall survival (B) using Kaplan-Meier analysis. The 
urves in red represent the good-prognosis group and the curves in green represent the poor- 
rognosis group. 

























The patients having disease-free survival information and those having overall survival 
inform tion from all the cohorts were combined and a survival plot was plotteda  using Kaplan-
the groups obtained in the correlation analysis.  It was seen that 
 
Figure 4.11: The 28-gene signature stratifies patients into subgroups with distinct disease-free 
survival (A) and overall survival (B) in Kaplan-Meier analysis (p <0.001, log-rank test).   The 
curves in red represent the good-prognosis group and the curves in green represent the poor- 
prognosis group.                
Meier analysis for patients with 
the 28-gene signature could stratify the patients into the two subgroups with distinct disease-free 
survival (log-rank test; p<0.0001; n=1337; Figure 4.11A) and distinct overall survival (log-rank 
test; p<0.0001; n=806; Figure 4.11B) with Kaplan-Meier analysis. The patients belonging to 
good-prognosis group had higher survival probabilities than those belonging to the poor- 
prognosis groups. These results confirm that the 28-gene signature is applicable to prognostic 
categorization for the clinical management of breast cancer based on the expression profiles 
generated on diverse DNA microarray platforms.  







This study sought to explore whether the 28-gene signature revealed common molecular features 
affecting breast and ovarian cancer. The ovarian cancer dataset from Bild et al. (38), that 
contained 124 patients was taken and the signature genes were identified in the dataset using 
atchminer (46). To avoid over-fitting in the validation, the dataset was randomly split into 
classified into good-prognosis (low-risk). The significance of this stratification scheme was 
tested by Kaplan-Meier analysis and log-rank test.  
The result of this analysis is shown in figure 4.12. This model generated significant 
patient stratification (log-rank test; p < 0.0001; Kaplan-Meier analyses; n=82; Figure 4.12A) for 
ovarian cancers in the training set. The prognostic model and the cut-off value identified from 
the training set were applied to the test set which resulted in significant patient stratification   
(log-rank test; p=0.0075; Kaplan-Meier analyses; n=42; Figure 4.12B). Thus the 28-gene 
signature reflected common biological processes involved in breast cancer and ovarian cancer 
metastases and relapse. The coefficients, z-score, and th
M
training and testing sets in the ratio of 2:1. The gene expression data contained in the training set 
was fitted in a Cox proportional hazard model, independent of traditional clinical-pathological 
parameters. The survival risk score for each patient in the training set was generated and the 
median of these scores was determined. This value (risk score: 0.3011433) was used as a cut-off 
to stratify patients in the training set and testing set into good-prognosis (low-risk) and poor-
prognosis (high-risk) groups. A patient with a risk score higher than the cut-off was classified 
into poor-prognosis (high-risk); whereas a patient with a risk score lower than the cut-off was 
e p-value of the variables (genes), 
obtained from the Cox proportional hazard model are as listed in Table 4.8. Signature genes with 





Table 4.8: The coefficients in the Cox proportional hazard model 
 Gene / 
Clone ID 














C18B11 221940_at -3.71E-03 0.996 0.003764 -0.9853 3.20E-01 








 208675_s_at 1.73E-03 1.002 0.000459 3.7655 1.70E-04 
FAT 201579_at 1.36E-03 1.001 0.00069 1.9761 4.80E-02 
FGF2 204421_s_at 7.03E-03 1.007 0.010632 0.661 5.10E-01 
FGF2 204422_s_at -1.57E-02 0.984 0.011846 -1.3219 1.90E-01 
IMAGE.182930 211868_x_at 5.67E-04 1.001 0.003814 0.1487 8.80E-01 
IMAGE.182930 215118_s_at -1.78E-04 1 0.003685 -0.0484 9.60E-01 
IMAGE.182930 216318_at 1.39E-02 1.014 0.01185 1.1696 2.40E-01 
IMAGE.182930 216541_x_at 1.05E-02 1.011 0.005294 1.9797 4.80E-02 
IMAGE.182930 216542_x_at 3.24E-03 1.003 0.001631 1.9872 4.70E-02 
IMAGE.182930 216557_x_at -8.85E-03 0.991 0.00317 -2.7927 5.20E-03 
IMAGE.182930 217022_s_at -1.79E-04 1 0.000185 -0.9654 3.30E-01 
IMAGE.182930 211636_at 1.22E-01 1.13 0.053242 2.2986 2.20E-02 
IMAGE.182930 214916_x_at 2.65E-03 1.003 0.001172 2.26 2.40E-02 
IMAGE.198917 212697_at -1.81E-03 0.998 0.001032 -1.7522 8.00E-02 
INPPL1 201598_s_at 5.61E-04 1.001 0.0008 0.7008 4.80E-01 
INSM1 206502_s_at 2.68E-03 1.003 0.00078 3.4405 5.80E-04 
IRF5 205468_s_at -1.43E-02 0.986 0.015558 -0.9184 3.60E-01 
MAP2K2 213487_at 4.60E-02 1.047 0.040941 1.1226 2.60E-01 
MAP2K2  213490_s_at -1.02E-03 0.999 0.003071 -0.3332 7.40E-01 
MCF2 208017_s_at -2.28E-02 0.977 0.009433 -2.4179 1.60E-02 
MCF2 217004_s_at -1.02E-02 0.99 0.008655 -1.1837 2.40E-01 
MCM2 202107_s_at -2.18E-03 0.998 0.000619 -3.5249 4.20E-04 
PBX2 202875_s_at -1.13E-02 0.989 0.003333 -3.388 7.00E-04 
PBX2 202876_s_at 2.58E-04 1 0.000756 0.3411 7.30E-01 
PBX2 211097_s_at 2.73E-02 1.028 0.008733 3.1296 1.80E-03 
PDGFRA 215305_at -4.87E-02 0.952 0.020093 -2.4255 1.50E-02 
PLSCR1 202430_s_at 1.50E-03 1.002 0.001342 1.1204 2.60E-01 
PLSCR1 202446_s_at -6.67E-05 1 0.000381 -0.1749 8.60E-01 
RAD50 208393_s_at -1.02E-02 0.99 0.002219 -4.5823 4.60E-06 
RAD50 209349_at 1.51E-02 1.015 0.006131 2.4621 1.40E-02 
RAD52 210630_s_at 1.23E-02 1.012 0.005932 2.0698 3.80E-02 
RAD52 211904_x_at -3.45E-02 0.966 0.013025 -2.6465 8.10E-03 
S100P 204351_at -6.75E-04 0.999 0.001109 -0.6086 5.40E-01 
SEC13L 221931_s_at 1.06E-03 1.001 0.001731 0.61 5.40E-01 
SLC25A5 200657_at -1.31E-04 1 0.00015 -0.8735 3.80E-01 
SMARCD2 201827_at 1.82E-03 1.002 0.000866 2.1042 3.50E-02 
SSBP1 202591_s_at 1.82E-03 1.002 0.000599 3.0458 2.30E-03 
TOMM70A 201512_s_at -7.12E-04 0.999 0.001645 -0.4326 6.70E-01 
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In this chapter we described how we used the population-based 28-gene expression signature to 
predict a poor outcome in breast cancer and ovarian as identified 
in our previous study (13) using the dataset from Sotiriou et al. (34), which contained 7,650 
genes assayed by cDNA microarrays on 99 patient samples. The 28-gene signature was validated 
on multiple published datasets that were generated on different microarray platforms. The 
nearest centroid classification algorithm (NCC) was used to stratify patients into gene signature-
defined prognostic groups by considering different cut-off values for different microarray 
platforms and clinical endpoints. 
tification for breast 
     
8-gene expression-defined prognostic risk groups had distinct clinical outcomes (log-rank test;       
 < 0.05; Kaplan-Meier analyses) within each clinical-pathological factor-defined subgroup and 
ere significant in providing additional prognostic information within each of the subgroups 
uch as lymph node-negative, lymph node-positive, ER-, ER+, and tumor grade II). The 
gnature also generated significant prognostic categorization in ovarian cancers in both training 
t (log-rank tests; p< 0.0001; n=82) and test set (log-rank tests; p=0.0075; n=42) in Kaplan-
eier analyses. 
One of the challenges faced in this study was to design a uniform prognostic mapping 
heme for the data from all the studied cohorts. Since the datasets used for validation contained 
ata generated on diverse DNA microarray platforms and clinical end-points, a single cut-off 
value could not be obtained for stratification of patients across all the datasets. This problem was 
S
 cancer. The 28-gene signature w
The 28-gene expression signature generated significant patient stra
cancer patients in both disease-free survival prediction (p < 0.0001; log-rank test; n=1337) and 














solve by selecting dd ifferent cut-off values for different platforms and endpoints. It was observed 
that the cut-off values identified, were consistently validated in multiple patient cohorts, except 
for one cut-off value that was selected for predicting relapse-free survival prediction for          
Loi et al. (41). 
This study confirmed the clinical applicability of the population-based 28-gene signature 
in predicting recurrence in breast cancer and ovarian cancer based on the expression profiles 
generated on diverse DNA microarray platforms. This is significant in the clinical management 
of breast cancer, as this molecular classification scheme would help the physicians to take proper 


















 of using gene expression as biomarkers for predicting the recurrence of breast 
cancer 
to identify the 
genomic instability gene signature. A population-based gene expression signature was used to 
redict breast and ovarian cancer outcomes. A prognostic patient-categorization scheme was 
ofiles generated on various microarray platforms. 
Since the datasets contained gene expression data that were generated on various microarray 
latforms, the cross-validation techniques in WEKA did not give us consistent observations in all 
the datasets. An innovative method was adopted for validation, namely, nearest centroid 
classification method (NCC), for classifying unknown samples in an effort to validate the 
erformance of the identified gene signature on numerous datasets. The NCC algorithm is 
efficient and robust with respect to irrelevant or novel attributes (14).  It was a challenging task 
to design a uniform prognostic mapping scheme for the data from all the studied cohorts. Since 
the datasets used for validation contained data generated on diverse DNA microarray platforms 
and clinical end-points, a single cut-off value could not be obtained for stratification of patients 
across all the datasets. This problem was solved by selecting different cut-off values for different 
platforms and endpoints. The significance of our research is that, both the gene signatures that 
provides the potential to refine breast cancer prognosis. Breast cancer patients with the 
same disease stage may have remarkably different clinical outcome and treatment response. 
There is a need to develop novel bioinformatic models for biomarker identification.   
In this study, the degree of genomic instability was integrated with gene expression 
patterns and a combination of several feature selection algorithms was used 
p







were identified, namely, the 28-gene population-based signature as well as the 12-gene genomic 
instability signature, could be used to classify a new breast cancer patient into different 
rognostic risk groups. 






The first part of our study suggests that, prognostication based on gene expression 
signatures is significant in the clinical management of breast cancer and could be augmented by 
quantitative measurement of nuclear DNA content. The second part of our study confirmed the 
practical applicability of the population-based gene signature in predicting recurrenc
rian cancer. The results of our study indicate that, stratification of patients into different 
subgroups on the basis of the prognosis profile, may be a useful means of guiding therapy in 
patients with breast cancer.  
Previous studies declare that the performance of a gene signature could be enhanced by 
combining it with other gene signatures (49). In the future analysis, we will explore whether the 
prediction accuracy of our gene signatures could be improved by integrating them with other 
gene signatures. Moreover, the identified gene signatures could be tested in other epithelial 
cancer types in addition to breast and ovarian cancer. Thus, gene-expression profiling opens up a 
new era in diagnosis, prognosis and treatment and helps to understand clearly, many of the 
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